The MRI focus group of the Ocrevus Data Strategy Group aims to identify sensitive imaging biomarkers in MS, to create a pool of imaging features extracted from all MS clinical trials, and to provide guidance on imaging endpoints for next studies. This group is led by Laura Gaetano.
PHC Imaging – MS Image Analysis Program. The PHC imaging group’s goal is to develop image analysis platform to automate extraction of current clinical trial imaging endpoints and identify prognostic and/or predictive biomarkers for MS. These efforts are led by Rick Carano and Thomas Bengtsson.
DevSci OMNI Biomarker Development is partnering with these imaging groups to understand the role of fluid and imaging biomarkers in multiple sclerosis. We’re leading investigation of fluid biomarkers such as neurofilament lightchain and association with MRI measures of progression, including brain volume and thalamic volume. We’re assisting with MRI interpretation to the PHC imaging group to support their algorithm development. Lastly, we’re collaborating with both groups to develop an integrated biomarker risk score in real-world MS cohorts supported through the PHC Neuroscience Program.
MRI brain features extracted from MS clinical trials
PHC Imaging – MS Image Analysis Program
Relationship between blood neurofilament light chain (NfL) level and brain volume change in relapsing and primary progressive multiple sclerosis (OPERA and ORATORIO)
Patients with high baseline NfL (above median, solid lines) show greater brain volume loss compared to those with low baseline NfL (below median, dotted lines) in each treatment arm of OPERA I & II and ORATORIO. Study individuals included RMS patients with MRI data at Weeks 24 and 96 (OPERA) and PPMS patients with MRI data at Weeks 24 and 120 (ORATORIO). IFN, interferon; NfL, neurofilament light; OCR, ocrelizumab; PBO, placebo; WBV, whole brain volume.
